Advertisement
PARIS, France, March 27, 2019 /PRNewswire-PRWeb/ -- "High-performing AI systems such as Transpara™ AI are becoming an essential tool for radiologists in screening and diagnostic mammography, to alleviate the workload and increase performance. Radiologists can use Transpara AI in the way that fits their needs the best: concurrently for support, for triaging of exams, or as an independent reader," says Nico Karssemeijer, CEO of ScreenPoint Medical.
"This partnership with Incepto™ will enable ScreenPoint Medical to address the market need for AI technologies by combining their expertise in the AI field with our knowledge and experience in delivering commercial and compatible solutions for our customers," adds Nico Karssemeijer.
With more than 50,000 breast cancer diagnosed in France and 4.4 million mammography exams performed every year, Transpara™ has the potential to improve significantly the quality and the efficacy of breast screening programs.
"It is an honour for Incepto to work with the ScreenPoint Medical team. They bring a unique expertise in the field of artificial intelligence and breast imaging. Today, the French market is expecting this kind of high-performing solution to support the continuous growth of mammography exams demand. With its outstanding user experience, we are convinced that Transpara technology will be a one-of-a-kind support for doctors within the coming years," explains Antoine Jomier, CEO of Incepto.
The distribution agreement with Incepto includes the full suite of Transpara AI solutions which have been clinically proven in peer reviewed publications to improve mammography reading performance and to achieve a breast cancer detection level equivalent to Radiologists.
Utilizing state-of-the-art image analysis and revolutionary deep learning technology, Transpara automatically identifies soft-tissue and calcification lesions in 2D and 3D mammograms. Findings are shown to radiologists via a unique interactive decision support interface, a scientifically-proven method that boosts reading performance, as opposed to traditional mammography CAD systems. In addition, based on the findings from all views of the exam, each case is categorized using the innovative Transpara Score, which categorizes the exams according to their risk of harbouring cancer and can be used to automatically triage exams with confidence.
Transpara is FDA cleared for digital mammography, has European regulatory approval (CE Mark) for use with digital mammography and digital breast tomosynthesis and is compatible with images from leading mammography systems.
About ScreenPoint Medical BV: ScreenPoint Medical develops image analysis technology for automated reading of mammograms and digital breast tomosynthesis exams, exploiting Big Data, Deep Learning and the latest developments in Artificial Intelligence. ScreenPoint Medical was founded in 2014 by Nico Karssemeijer and Michael Brady, two experts in breast imaging, machine learning, computer vision, and computer-aided detection. The main office is in Nijmegen, The Netherlands. For more information, please contact [email protected]
About Incepto: The first concrete applications of artificial intelligence are coming.
The real challenge today lies in the uses. It is about converting technology into practical applications: integrating it into the clinical workflow, identifying use cases, creating easy-to-use interfaces, equipping and training physicians.
This is precisely where Incepto comes in. Today a hundred applications using artificial intelligence, more or less advanced, exist or are under development in the world. Incepto's mission is twofold: to help physicians identify, access and use the best-performing solutions; and create with them new applications, tailored to their specific needs. Incepto is both distributor and producer of solutions.
The ambition is simple: to help doctors make full use of the applications of technology to save time, improve the quality of their diagnosis and ultimately save lives. The main office is in Paris, France. For more information, please contact [email protected]
SOURCE ScreenPoint Medical
Advertisement
"This partnership with Incepto™ will enable ScreenPoint Medical to address the market need for AI technologies by combining their expertise in the AI field with our knowledge and experience in delivering commercial and compatible solutions for our customers," adds Nico Karssemeijer.
With more than 50,000 breast cancer diagnosed in France and 4.4 million mammography exams performed every year, Transpara™ has the potential to improve significantly the quality and the efficacy of breast screening programs.
"It is an honour for Incepto to work with the ScreenPoint Medical team. They bring a unique expertise in the field of artificial intelligence and breast imaging. Today, the French market is expecting this kind of high-performing solution to support the continuous growth of mammography exams demand. With its outstanding user experience, we are convinced that Transpara technology will be a one-of-a-kind support for doctors within the coming years," explains Antoine Jomier, CEO of Incepto.
The distribution agreement with Incepto includes the full suite of Transpara AI solutions which have been clinically proven in peer reviewed publications to improve mammography reading performance and to achieve a breast cancer detection level equivalent to Radiologists.
Utilizing state-of-the-art image analysis and revolutionary deep learning technology, Transpara automatically identifies soft-tissue and calcification lesions in 2D and 3D mammograms. Findings are shown to radiologists via a unique interactive decision support interface, a scientifically-proven method that boosts reading performance, as opposed to traditional mammography CAD systems. In addition, based on the findings from all views of the exam, each case is categorized using the innovative Transpara Score, which categorizes the exams according to their risk of harbouring cancer and can be used to automatically triage exams with confidence.
Transpara is FDA cleared for digital mammography, has European regulatory approval (CE Mark) for use with digital mammography and digital breast tomosynthesis and is compatible with images from leading mammography systems.
About ScreenPoint Medical BV: ScreenPoint Medical develops image analysis technology for automated reading of mammograms and digital breast tomosynthesis exams, exploiting Big Data, Deep Learning and the latest developments in Artificial Intelligence. ScreenPoint Medical was founded in 2014 by Nico Karssemeijer and Michael Brady, two experts in breast imaging, machine learning, computer vision, and computer-aided detection. The main office is in Nijmegen, The Netherlands. For more information, please contact [email protected]
About Incepto: The first concrete applications of artificial intelligence are coming.
The real challenge today lies in the uses. It is about converting technology into practical applications: integrating it into the clinical workflow, identifying use cases, creating easy-to-use interfaces, equipping and training physicians.
This is precisely where Incepto comes in. Today a hundred applications using artificial intelligence, more or less advanced, exist or are under development in the world. Incepto's mission is twofold: to help physicians identify, access and use the best-performing solutions; and create with them new applications, tailored to their specific needs. Incepto is both distributor and producer of solutions.
The ambition is simple: to help doctors make full use of the applications of technology to save time, improve the quality of their diagnosis and ultimately save lives. The main office is in Paris, France. For more information, please contact [email protected]
SOURCE ScreenPoint Medical
